© 2022 MJH Life Sciences and CGTLive™. All rights reserved.
© 2022 MJH Life Sciences™ and CGTLive™. All rights reserved.
Oncternal will soon initiate a phase 1/2 dose-escalation study of ONCT-808.
The vice president of oncology and research and development at Exuma Biotech discussed the company’s platforms, including CAR-TaNK cells.
Newborn Cell Therapies Group at Monash University has received a $50,000 grant from Lions Cord Blood foundation.